A phase I trial of enzastaurin in patients with recurrent gliomas.
about
Exciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaGlycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingNovel delivery strategies for glioblastomaThe role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Experimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.Pathway inhibition: emerging molecular targets for treating glioblastoma.Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.Standards of care and novel approaches in the management of glioblastoma multiforme.AKT/GSK3β Signaling in Glioblastoma.Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Anti-angiogenic therapy in glioma.Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cellsA phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
P2860
Q24632791-3E3DA98B-1548-4F1B-9DFE-2567877130DBQ26768475-AB387321-861A-4788-A09E-D3FA02A36DBFQ27006099-6ABA63EB-A71F-47C5-BB3F-C86E637A0E52Q30797166-018F93AD-27BC-4EB3-8D29-F3EEE1506A8EQ33418912-387112C4-BF42-464D-AE25-A64DDD530517Q34127138-C3E71A4B-7351-438E-90BA-7BA1785F918BQ34132781-9DBF5B77-4DED-4F0C-B4E8-1CA95135B9EDQ35021359-BF14E157-3205-4F34-A4A4-E34BDBB28659Q35684292-31B7F95F-7B06-4ED0-9B95-5F18727F514EQ36816535-2FAF458F-0EB0-4EEE-B4D5-88506769CDD4Q37109823-6205BF69-1400-46B9-A17D-885338BD5452Q37525881-95AB857B-DA8B-4D5C-9D97-6322D253F74CQ37710163-27BCF004-9183-4C4A-B84C-28CF92E10029Q37736273-C9C6B5D6-0EBE-4EE4-B0DE-1D2EC4B3DEDBQ37877409-960CDF49-87F2-4313-97F9-AF33DBAB22BDQ38390695-0FF0E85E-4779-47CA-A75E-148CBF864ACBQ38775522-FDE0A4F1-F9FB-46FF-AB4D-B427FD48300CQ38956949-EEB3E989-59B1-427C-B8F3-14D5CA773ED9Q39264679-D8F9C9BE-73F1-426B-A64D-4BB46348EB9DQ39584277-B71F5ED6-5ABF-467D-B952-8320176A06F3Q55463279-2CFC3624-B0EF-4941-91AE-105DA87F45AD
P2860
A phase I trial of enzastaurin in patients with recurrent gliomas.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I trial of enzastaurin in patients with recurrent gliomas.
@ast
A phase I trial of enzastaurin in patients with recurrent gliomas.
@en
type
label
A phase I trial of enzastaurin in patients with recurrent gliomas.
@ast
A phase I trial of enzastaurin in patients with recurrent gliomas.
@en
prefLabel
A phase I trial of enzastaurin in patients with recurrent gliomas.
@ast
A phase I trial of enzastaurin in patients with recurrent gliomas.
@en
P2093
P1476
A phase I trial of enzastaurin in patients with recurrent gliomas.
@en
P2093
Donald Thornton
Howard A Fine
Jennifer Walling
Kraig Moore
Luna Musib
Lyndon Kim
Paul S Albert
Svetlana Kotliarova
Teri N Kreisl
P304
P356
10.1158/1078-0432.CCR-08-3071
P407
P577
2009-05-05T00:00:00Z